Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Adrixetinib - Qurient Therapeutics

Next Previous
Drug Profile

Adrixetinib - Qurient Therapeutics

Alternative Names: Axl/Mer/CSF1R triple Inhibitor; Q-702

Latest Information Update: 28 Sep 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator The Lead Discovery Center; The Max Planck Institute of Biochemistry; Vichem Chemie
  • Developer Merck & Co; Qurient Co
  • Class Amides; Antineoplastics; Ethers; Fluorinated hydrocarbons; Pyrazoles; Pyridines; Quinolines; Small molecules
  • Mechanism of Action Axl receptor tyrosine kinase inhibitors; Macrophage colony-stimulating factor receptor antagonists; Proto-oncogene protein c-mer inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours
  • Phase I Acute myeloid leukaemia; Haematological malignancies
  • No development reported Non-small cell lung cancer

Most Recent Events

  • 28 Sep 2026 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO)
  • 14 May 2026 Chemical structure information added
  • 22 Apr 2026 Pharmacodynamics data from a preclinical trial in Solid tumours presented at the 117th Annual Meeting of the American Association for Cancer Research (AACR-2026)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top